There is still work to be done; it is good that things are turning, and they needed to, but it is still a WIP. The revenue may well be $400m, but the company needs the revenue to continue to grow because the company overheads needs revenue of $400m *just* for EBITDA break even.
If we take the 4 months we know; there's $375m revenue without a positive
I'm a fan of the CEO - I think he is on the right track, and the team around him now have a clear vision. Think it will take more than the 1/2 yearly to tell the story. Probably another 6 months, so 3rd 1/4.
In BPD, not sure that Nextstellis is delivering a positive run-rate, think they still need Maxwell to come in and fire. But we *need* to continue to see growth as the revenue of this product delivers the biggest benefit to the bottom line.
Be nice to see additional costs savings as well - but that's a balance when also trying to grow product(s).
- Forums
- ASX - By Stock
- MYX
- Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference
Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference, page-12
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.71 |
Change
0.070(1.51%) |
Mkt cap ! $400.7M |
Open | High | Low | Value | Volume |
$4.67 | $4.75 | $4.62 | $953.1K | 203.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1236 | $4.71 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.72 | 620 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1236 | 4.710 |
1 | 13000 | 4.700 |
1 | 190 | 4.690 |
2 | 190 | 4.680 |
1 | 190 | 4.670 |
Price($) | Vol. | No. |
---|---|---|
4.730 | 190 | 1 |
4.740 | 190 | 1 |
4.750 | 115 | 1 |
4.760 | 188 | 1 |
4.770 | 188 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online